Complications associated with sedative and neuromuscular blocking drugs in critically ill patients

R. C. Prielipp, D. B. Coursin, K. E. Wood, M. J. Murray

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Pharmacologic administration of sedatives is used routinely in the care of the critically ill to enhance patient comfort and optimize care. Long-term administration of NMB drugs is far less frequent but often occurs in patients with greater organ dysfunction. The experience of several authors using NMB drugs in the ICU is summarized in Table 5. Both classes of drugs have potential untoward effects. Some are readily predictable; others are not. NMB drugs enjoy a long record of safe, effective use during the perioperative period, but certain issues linger in defining appropriate administration to critically ill patients. Major concerns focus on the appropriate drug selection and delivery, monitoring, and neuromuscular recovery of patients who receive NMB drugs for longer than 24 hours. The development of myopathy and paresis has been increasingly recognized after prolonged use of NMB drugs in the ICU. Further investigation needs to fully characterize this process, identify those at risk, and outline a mechanism to prevent or limit the injury. Prolonged weakness may occur secondary to changes in the basic pharmacology and elimination of NMB drugs in ICU patients. Pathophysiologic changes in the nerve, muscle, or neuromuscular junction may also play a role in the development of some cases of prolonged weakness or myopathy after discontinuation of NMB drugs. Concerns about the potential for direct or indirect toxicity of NMB drugs to skeletal muscle and in the CNS remain. Resolution of these issues will improve the selection and optimal administration of sedative and NMB drugs in the ICU setting.

Original languageEnglish (US)
Pages (from-to)983-1003
Number of pages21
JournalCritical Care Clinics
Volume11
Issue number4
StatePublished - 1995
Externally publishedYes

Fingerprint

Hypnotics and Sedatives
Critical Illness
Pharmaceutical Preparations
Muscular Diseases
Neuromuscular Monitoring
Perioperative Period
Neuromuscular Junction
Paresis
Drug-Related Side Effects and Adverse Reactions
Skeletal Muscle
Pharmacology
Muscles
Wounds and Injuries

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Prielipp, R. C., Coursin, D. B., Wood, K. E., & Murray, M. J. (1995). Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. Critical Care Clinics, 11(4), 983-1003.

Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. / Prielipp, R. C.; Coursin, D. B.; Wood, K. E.; Murray, M. J.

In: Critical Care Clinics, Vol. 11, No. 4, 1995, p. 983-1003.

Research output: Contribution to journalArticle

Prielipp, RC, Coursin, DB, Wood, KE & Murray, MJ 1995, 'Complications associated with sedative and neuromuscular blocking drugs in critically ill patients', Critical Care Clinics, vol. 11, no. 4, pp. 983-1003.
Prielipp, R. C. ; Coursin, D. B. ; Wood, K. E. ; Murray, M. J. / Complications associated with sedative and neuromuscular blocking drugs in critically ill patients. In: Critical Care Clinics. 1995 ; Vol. 11, No. 4. pp. 983-1003.
@article{b4e2e44f24af48d197018fd1bbfe8786,
title = "Complications associated with sedative and neuromuscular blocking drugs in critically ill patients",
abstract = "Pharmacologic administration of sedatives is used routinely in the care of the critically ill to enhance patient comfort and optimize care. Long-term administration of NMB drugs is far less frequent but often occurs in patients with greater organ dysfunction. The experience of several authors using NMB drugs in the ICU is summarized in Table 5. Both classes of drugs have potential untoward effects. Some are readily predictable; others are not. NMB drugs enjoy a long record of safe, effective use during the perioperative period, but certain issues linger in defining appropriate administration to critically ill patients. Major concerns focus on the appropriate drug selection and delivery, monitoring, and neuromuscular recovery of patients who receive NMB drugs for longer than 24 hours. The development of myopathy and paresis has been increasingly recognized after prolonged use of NMB drugs in the ICU. Further investigation needs to fully characterize this process, identify those at risk, and outline a mechanism to prevent or limit the injury. Prolonged weakness may occur secondary to changes in the basic pharmacology and elimination of NMB drugs in ICU patients. Pathophysiologic changes in the nerve, muscle, or neuromuscular junction may also play a role in the development of some cases of prolonged weakness or myopathy after discontinuation of NMB drugs. Concerns about the potential for direct or indirect toxicity of NMB drugs to skeletal muscle and in the CNS remain. Resolution of these issues will improve the selection and optimal administration of sedative and NMB drugs in the ICU setting.",
author = "Prielipp, {R. C.} and Coursin, {D. B.} and Wood, {K. E.} and Murray, {M. J.}",
year = "1995",
language = "English (US)",
volume = "11",
pages = "983--1003",
journal = "Critical Care Clinics",
issn = "0749-0704",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Complications associated with sedative and neuromuscular blocking drugs in critically ill patients

AU - Prielipp, R. C.

AU - Coursin, D. B.

AU - Wood, K. E.

AU - Murray, M. J.

PY - 1995

Y1 - 1995

N2 - Pharmacologic administration of sedatives is used routinely in the care of the critically ill to enhance patient comfort and optimize care. Long-term administration of NMB drugs is far less frequent but often occurs in patients with greater organ dysfunction. The experience of several authors using NMB drugs in the ICU is summarized in Table 5. Both classes of drugs have potential untoward effects. Some are readily predictable; others are not. NMB drugs enjoy a long record of safe, effective use during the perioperative period, but certain issues linger in defining appropriate administration to critically ill patients. Major concerns focus on the appropriate drug selection and delivery, monitoring, and neuromuscular recovery of patients who receive NMB drugs for longer than 24 hours. The development of myopathy and paresis has been increasingly recognized after prolonged use of NMB drugs in the ICU. Further investigation needs to fully characterize this process, identify those at risk, and outline a mechanism to prevent or limit the injury. Prolonged weakness may occur secondary to changes in the basic pharmacology and elimination of NMB drugs in ICU patients. Pathophysiologic changes in the nerve, muscle, or neuromuscular junction may also play a role in the development of some cases of prolonged weakness or myopathy after discontinuation of NMB drugs. Concerns about the potential for direct or indirect toxicity of NMB drugs to skeletal muscle and in the CNS remain. Resolution of these issues will improve the selection and optimal administration of sedative and NMB drugs in the ICU setting.

AB - Pharmacologic administration of sedatives is used routinely in the care of the critically ill to enhance patient comfort and optimize care. Long-term administration of NMB drugs is far less frequent but often occurs in patients with greater organ dysfunction. The experience of several authors using NMB drugs in the ICU is summarized in Table 5. Both classes of drugs have potential untoward effects. Some are readily predictable; others are not. NMB drugs enjoy a long record of safe, effective use during the perioperative period, but certain issues linger in defining appropriate administration to critically ill patients. Major concerns focus on the appropriate drug selection and delivery, monitoring, and neuromuscular recovery of patients who receive NMB drugs for longer than 24 hours. The development of myopathy and paresis has been increasingly recognized after prolonged use of NMB drugs in the ICU. Further investigation needs to fully characterize this process, identify those at risk, and outline a mechanism to prevent or limit the injury. Prolonged weakness may occur secondary to changes in the basic pharmacology and elimination of NMB drugs in ICU patients. Pathophysiologic changes in the nerve, muscle, or neuromuscular junction may also play a role in the development of some cases of prolonged weakness or myopathy after discontinuation of NMB drugs. Concerns about the potential for direct or indirect toxicity of NMB drugs to skeletal muscle and in the CNS remain. Resolution of these issues will improve the selection and optimal administration of sedative and NMB drugs in the ICU setting.

UR - http://www.scopus.com/inward/record.url?scp=0028808227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028808227&partnerID=8YFLogxK

M3 - Article

C2 - 8535989

AN - SCOPUS:0028808227

VL - 11

SP - 983

EP - 1003

JO - Critical Care Clinics

JF - Critical Care Clinics

SN - 0749-0704

IS - 4

ER -